News & Analysis on Clinical Trial Services & Contract Research And Development
EUSA Pharma, Carsten Thiel and Darrel Cohen
By Ben Hargreaves
- Last updated on
EUSA Pharma makes two appointments, with Carsten Thiel (pictured, left) joining as president of its European business and Darrel Cohen (pictured, right) becoming head of clinical development.
The appointment of Thiel sees him return to work half a year after his departure as CEO of Abeona Therapeutics under a cloud, a role he had held for only six months at the time.
At the time, Abeona stated that his position had been terminated due to the ‘personal misconduct’ following an investigation by independent members of the company’s board of directors. The committee found that Thiel had violated the company’s code of business conduct and ethics, which led to his departure from the business.
EUSA’s announcement makes no mention of the circumstances under which he left Abeona, with Thiel himself stating that, “I am honoured to lead the expansion of [the company’s] commercialisation activities in Europe”.
Prior to his brief stint at Abeona, Thiel had worked as CCO at Alexion and spent seven years as VP of Amgen’s European business.
Cohen arrives at the company after nearly 13 years at Pfizer, where he oversaw clinical development.
Lee Morley, EUSA Pharma’s CEO, said, “We are delighted to welcome Thiel and Cohen to EUSA. Both bring significant experience, vision and proven executional skills to the company, which will prove invaluable as we continue the rapid expansion in Europe.”
The company is currently working on the commercial rollout of Fotivda (tivozanib), Qarziba (dinutuximab), and Sylvant (siltuximab).